Carclo Regulatory News (CAR)



31 March 2015

Carclo plc ("Carclo")

Board change

The board announces that David Toohey has been appointed to the Carclo plc board as a non-executive director with effect from 1 April 2015.

David Toohey has over 30 years' experience in international business, the last 20 of which have been in medical devices and the In Vitro Diagnostics ('IVD') industry. He has been Chief Executive Officer of Syncrophi Systems Limited ("Syncrophi"), since 2012. He joined Syncrophi from Alere Inc, the global diagnostics and health management company, where he spent 11 years in senior managerial roles, latterly as President of International Business Operations. Mr. Toohey held various Executive positions at Boston Scientific Corporation, Bausch & Lomb, Inc., Digital Equipment Corp. and Mars, Inc. He has been an Independent Non-Executive Director at EKF Diagnostics Holdings plc since August 2014.

There are no further disclosures relating to David Toohey required under paragraph 9.6.13R of the Listing Rules.

Notes to editors

Carclo plc is a public company whose shares are quoted on the London Stock Exchange.

Carclo's strategy is to develop and expand its key manufacturing assets where there remain significant further opportunities to drive value. To enhance profit margins the group has been investing in new technologies.

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, mainly for medical products. The balance of revenue is derived mainly from the design and supply of specialised injection moulded LED based lighting systems to the low volume premium automotive industry.